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ABSTRACT 
Familial cerebral cavernous malformations (FCCM) are vascular malformations 
inherited as an autosomal-dominant condition. Mutations in three genes have been 
described so far. Extra-neurological involvement includes retinal and cutaneous 
vascular malformations. Hyperkeratotic cutaneous vascular malformations are 
considered specific for FCCM and are always associated to KRIT1/CCM1 mutations. 
We report the case of a 40-years-old male patient with multiple cerebral cavernomas 
presenting with an asymptomatic isolated hyperkeratotic well-demarcated dark-blue 
plaque of ca. 0.5x1cm diameter on the left heel. Histologic examination showed a 
superficial, verrucous haemangioma with verrucous hyperorthokeratosis, slight 
papillomatosis and acanthosis of the epidermis as well as multiple strongly dilated 
thin-walled vessels in the superficial dermis. Based on these findings, a case of 
FCCM was suspected and mutation analysis was performed, which revealed a 
mutation in the exon 12 of KRIT1 (c.1201C>T). 
 
INTRODUCTION 
Cavernous vascular malformations affecting about 0.5 percent of the population 
worldwide can occur anywhere in the body, but produce serious signs and symptoms 
only when they occur in the central nervous system. Patients with cerebral cavernous 
malformations may experience headaches, seizures, paralysis, hearing or vision 
deficiencies, and cerebral haemorrhage. The location and number of cerebral 
cavernous malformations determine the severity of this disorder. Approximately 25% 
of individuals with cerebral cavernous malformations never experience any related 
medical problems.  
Familial cerebral cavernous malformations (FCCM) are inherited as an autosomal-
dominant condition. Mutations in three genes (KRIT1 /CCM1, MGC4607/CCM2 and 
PDCD10/CCM3) account for 70 to 80% of all cases of familial cerebral cavernous 
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malformations. The remaining 20 to 30% of cases may be due to unidentified genes 
or to other unknown causes. The precise functions of the so far identified genes are 
not fully understood, but they most likely play a role in embryonic angiogenesis. 
Extra-neurological involvement in patients with FCCM includes retinal and cutaneous 
vascular malformations. Cutaneous involvement is seen in 9% of FCCM patients. 
Hyperkeratotic cutaneous vascular malformations are considered specific for FCCM 
and are always associated to KRIT1/CCM1 mutations. Dermatologists should be 
aware of this entity, since they can play an important role in identifying discrete but 
typical skin changes, leading to identification of the causing mutation. 
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CASE REPORT 
We report the case of a 40-years-old male patient with seizures since the age of 14 
due to multiple cerebral cavernomas, treated by oxycarbazepine. Familial history for 
cerebral cavernomas was negative, but an uncle was known for a "brain tumor" (no 
exact medical diagnosis available), and the grandmother as well as the nephew of 
the patient had suffered a stroke. The patient was referred to the department of 
Dermatology by his neurologist for the evaluation of a dark-blue spot on the left heel, 
which had been present for many years. The lesion presented clinically as an 
asymptomatic isolated hyperkeratotic well-demarcated plaque, dark-blue in the 
centre with a reddish border, measuring ca. 0.5x1cm diameter (Figure 1). Histologic 
examination showed a superficial, verrucous haemangioma with verrucous 
hyperorthokeratosis, slight papillomatosis and acanthosis of the epidermis as well as 
multiple strongly dilated thin-walled vessels in the superficial dermis (Figure 2a). The 
vessels stained positive for the endothelial cell marker CD31 (Figure 2b) but were 
negative for the lymphatic endothelial cell marker D2-40 (Figure 2c). Based on these 
findings, we suspected a FCCM and performed a mutation analysis on the 16 coding 
exons of the KRIT1 gene by sequencing and QMPSF, revealing a mutation in the 
exon 12 (c.1201C>T) leading to the replacement of a glutamine by a stop codon at 
position 401 (p.Q401X), typical of those found in cavernoma (Florence Riant: found 
in how many% of patients?). The lesion did not disturb the patient, so it was not 
completely excised. The mutation analysis was followed by genetic counselling; 
indeed, the autosomal transmission implies a 50% risk for the children of the patient 
to inherit the mutation and a higher relative risk to develop cerebral cavernomas 
compared to the general population, although the penetrance is incomplete. A 
preimplantation genetic testing can be proposed to the affected patients. 
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DISCUSSION 
Cerebral cavernomas are vascular malformations of the central nervous system 
characterized by enlarged capillary cavities without intervening brain parenchyma. 
The prevalence in the general population is estimated as 0.1-0.5%, with familial 
incidence close to 20%.1 Three CCM genes have been identified so far 
(KRIT1/CCM1, MGC4607/CCM2, PDCD10/CCM3). 
The association between cavernous haemangiomas of the retina and brain with 
vascular lesions of skin has been reported in the literature since 1971,2-5 but the 
responsible mutations has been first identified since 1999.6-8 A series analysis of 417 
patients revealed cutaneous vascular malformations in 9% of cases, including 15 
hyperkeratotic cutaneous capillary venous malformations (HCCVM, 39%), 13 
capillary malformations (34%), 8 venous malformations (21%) and 2 unclassified 
lesions. All patients with HCCVM had a KRIT1/CCM1 mutation and CCM1 was the 
most frequently mutated gene in cutaneous vascular malformations-FCCM patients.9 
This case illustrate the important role the dermatologist can play in identifying 
discrete but typical skin changes, leading to identification of the causing mutation. 
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FIGURES LEGENDS 
Figure 1:  
Well demarcated verrucous plaque on the left heel of the patient 
Figure 2:  
Histological findings: Hyperkeratosis and numerous dilated capillary and venous 
vessels in the upper dermis seen in the hematoxilin-eosin stain (a). The dilated 
vessels are highlighted in the CD31 stain (b), but are negative for the lymph-vessel 
marker D2-40 (c). 
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